Propanc Biopharma is progressing key bioanalytical and immunogenicity assay developments to support its upcoming Phase 1b First-In-Human trial of PPC-001, a novel cancer treatment, in up to 50 advanced cancer patients. The company reported encouraging stability and detection results for PPC-001 components in human blood, successful mass spectrometry application, and progress in anti-drug antibody assay development. These efforts aim to optimize pharmacokinetic methods and ensure reliable clinical sample analysis, laying the groundwork for evaluating PPC-001's effects in cancer treatment. This advancement marks a significant step toward clinical evaluation of a unique proenzyme-based therapy targeting cancer spread and recurrence.
Propanc Biopharma's progress in bioanalytical and immunogenicity assay development for its Phase 1b cancer trial is presented here with relevant market data. For readers following the health sector, here is Pluang's market snapshot as of Oct 30, 2026 18:43 WIB: out of 150 priced health-sector US stocks, 71 rose and 72 fell. Notable movers include BTSG at USD 64.06 with a 1-day change of +6.38% and a typical hold time of 10 days, TXG at USD 76.56 down 6.12% with a 92-day hold, and AZN at USD 183.17 up 5.03% with a 126-day hold time.
FreightCar America disclosed on October 19, 2026, that it removed 1,285 railcars from its backlog after a customer was unlikely to fulfill contractual obligations, causing its stock to drop 31.4% to $4.02. This sharp decline has led Glancy Prongay Wo...
FirstCash Holdings, Inc. shares fell 14.75% following the October 22, 2026 disclosure of its third quarter financial results, which showed a 28% year-over-year decline in operating income for its American First Finance segment to $33 million. The com...
The global screw compressors market is projected to grow from $13.97 billion in 2026 to $18.38 billion by 2031, at a CAGR of 5.66%. Growth is fueled by rising industrial automation, energy-efficiency regulations, and demand in manufacturing, oil and ...
Enova International's stock fell 23.43% after the company withdrew its application to acquire Grasshopper Bancorp and become a bank holding company. The withdrawal was due to unclear regulatory standards and political pressures cited by Enova. This s...
The global dialysis machines market is forecasted to grow from $17.89 billion in 2026 to $31.54 billion by 2035, at a CAGR of 6.5%. Growth is fueled by rising chronic kidney disease cases, expanding dialysis infrastructure, and innovations like home ...
